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Abstract
Background The 5-year survival rates for localized lipo-
sarcomas reportedly vary from 75% to 91% with histologic
grade as the most important prognostic factor. However, it
is unclear which other factors, including the initial surgery
quality and recurrent tumors, influence survival in localized
liposarcomas (LPS).
Questions/Purposes We analyzed factors (including
AJCC staging system) influencing survival and local control
of resectable LPS of the extremities/trunk wall and the
impact of surgery quality and tumor status and type of dis-
ease recurrences according to pathological subtype.
Methods We retrospectively reviewed 181 patients with
localized LPS: 110 were treated for primary tumors, 50 for
recurrent tumors, and 21 for wide scar resection after
unplanned nonradical resection. We determined survival
rates and examined factors influencing survival. The min-
imum followup was 4 months (median, 52 months; range,
4–168 months).
Results Five-year disease-specific (DSS), disease-free
(DFS), and local relapse-free survival (LRFS) rates were:
80%, 58%, and 75%, respectively. Five-year local relapse-
free survival rates for primary versus clinically recurrent
tumor versus scar after nonradical resection were: 86.1%,
52.1%, and 73.3%, respectively. The following were inde-
pendent negative prognostic factors for DSS (AJCC Stage
C IIb), DFS (Grade 3; clinical recurrence; skin infiltration),
and LRFS (clinical recurrence; R1 resection). An unplanned
excision, although influencing local relapse-free survival,
had no impact on disease-specific survival (calculated from
date of first excision 5-year rate of 80%, considering impact
of combined treatment of clinical recurrence/scar).
Conclusions We confirmed the value of AJCC staging
for predicting disease-specific survival in extremity/trunk
wall LPS. Radical reresection of scar after nonradical pri-
mary tumor resection (+ radiotherapy) seems to improve
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disease-free and local relapse-free survival in liposarco-
mas. Patients with unplanned excision can be cured when
referred to a sarcoma unit.
Level of Evidence Level IV, prognostic study. See the
Guidelines for Authors for a complete description of levels
of evidence
Introduction
Soft tissue sarcomas, a heterogeneous group of malignan-
cies, are challenging to diagnose and treat because of their
rarity, various clinical presentations, disease course, and
multiple pathological subtypes. Liposarcomas are the most
common soft tissues tumors (with the exception of gas-
trointestinal stromal tumors) [16] and well-defined
pathologically type of soft tissue sarcomas occurring in
adults. Like with other sarcomas, treatment is recom-
mended in referral centers with multidisciplinary expertise
[2]. However, in reality, a substantial number of patients
with primary soft tissue sarcomas are still treated in non-
referral centers by unplanned resection of the tumor and
then referred to tertiary institutions [20, 28]. Several con-
temporary studies, each of which included more than
100 cases, analyzed the outcomes of patients with localized
liposarcomas [7, 9, 12, 17, 18]. These studies suggest
5-year survival rates ranged from 75% to 91% with his-
tologic grade as the most important prognostic factor.
The American Joint Committee on Cancer (AJCC)
staging system recently proposed a new staging system for
soft tissue sarcomas incorporating a three-tiered grading
system and nodal metastases classified as Stage III disease
[4, 5]. This system has been never tested for evaluation of
cohort of localized liposarcomas. It is also unclear how
other prognostic factors, including the quality of the initial
surgery (ie, complete or incomplete excision) and other
factors, including recurrent tumors, influence survival in
localized soft tissue sarcomas. We have evaluated in the
study homogenous series of liposarcomas originating from
extremities or the trunk wall, which were analyzed jointly
because of similar prognosis and approach, contrary to
retroperitoneal or head and neck liposarcomas [17].
The aims of the study were to determine: (1) prognostic
factors having an influence on disease-specific survival,
disease-free survival, and local relapse-free survival,
including the new AJCC staging system, based on a
homogenous cohort of localized, resectable liposarcomas
of the extremities/trunk wall treated with curative intent in
a tertiary referral sarcoma center; (2) the impact of quality
of surgery and tumor status (primary versus clinically
recurrent versus scar after inadequate surgery); and (3) type
of disease recurrences according to pathological subtype of
liposarcoma.
Patients and Methods
We retrospectively reviewed all 190 adult patients with
localized, resectable liposarcomas originating from the
extremities or trunk wall treated with curative intent in a
tertiary sarcoma center between 1996 and 2008. Eight
patients were excluded owing to loss to followup after
surgery. These exclusions left 181 patients with complete
clinical-pathological data (Table 1). Median age at diag-
nosis of the 181 patients was 58 years (range, 18–89 years).
Most primary tumors were located in the lower extremity
(76%) followed by the trunk wall (14%) and upper
extremity (10%). At presentation in the tertiary center,
110 patients (61%) had untreated primary tumors, 50
(27.5%) had clinical local recurrence after resection at an
outside facility, and 21 (11.5%) had only scar (without
clinically detectable tumor) after primary nonradical un-
planned resection at an outside sarcoma center. All cases
were classified according to the AJCC staging system 7th
edition [4, 5]. Minimum followup was 4 months (median,
52 months; range, 4–168 months; only 11 survivors, 6%
had minimum followup less than 12 months). No patients
were recalled specifically for this study; all data were
obtained from medical records. Analysis of clinicopatho-
logic data had been approved by the local bioethical
committee according to Good Clinical Practice Guidelines.
All 181 patients underwent wide surgical resection
(whenever possible) combined, after multidisciplinary
assessment, with adjuvant radiotherapy (pre- or postoper-
ative) in the majority of cases (only five extremity
amputations were primarily performed). Patients did not
receive any adjuvant chemotherapy. We considered wide
excision combined with adjuvant external beam radiation
therapy as standard treatment in the majority of soft tissue
sarcomas as required by national and international guide-
lines [2, 19, 30] and 154 of the 181 patients had additional
radiotherapy (with exception of all patients in Stage Ia and
part in Stage Ib) based on the decision of the multidisci-
plinary team. In cases of positive margins after surgery
preceded by preoperative surgery, the additional boost on
the tumor bed was added in individual cases.
Followup information was obtained during regular out-
patient visits. Routine surveillance was recommended
every 3 months during the first 2 years, every 4 months in
Year 3, every 6 months in Years 4 to 5, and thereafter
annually. Patients with Stage IA liposarcomas were seen
every 6 months after the first year. Posttreatment followup
consisted of physical examination and routine imaging
investigations. We used CT or radiography for chest wall
tumors, abdominal cavity evaluation in myxoid/round-cell
liposarcoma subtype (ultrasound alternating with CT), and
ultrasound or MR for wide scar resection according to
national guidelines [30]. All available medical and
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histopathological records were reviewed; pathological
diagnoses were reconfirmed in our center.
For the survival analysis, Kaplan-Meier estimator was
used with the log-rank tests to compare survival between
subgroups of patients (listed subsequently). We determined
disease-specific survival, disease-free survival, and local
recurrence-free survival calculated from the date of tumor
resection at the referral center to the date of death resulting
from disease, recurrence, or local relapse, respectively, or
to the last followup date. We also calculated disease-
specific survival from the date of the first tumor resection
(outside or in referral center) to the date of death resulting
from disease progression or last followup. All deaths from
other reasons were recorded as censored. Clinical and
pathological parameters as follows: sex, age (\ 49 versus
49–59 versus [ 59 years), primary tumor site (extremity
versus trunk wall; lower versus upper extremity), histo-
logical grade (1 versus 2 versus 3), tumor size (B 5 versus
[ 5 cm), tumor status at the beginning of therapy in the
tertiary center (primary tumor versus clinical recurrence
versus scar after nonradical surgery), the fact of biopsy
before primary surgery (yes versus no), margin status at
final surgery (R0, microscopically radical resection versus
R1, microscopically nonradical, but macroscopically radi-
cal resection), histological subtype (myxoid/round cell
versus pleomorphic versus well-differentiated), skin infil-
tration by the tumor/ulceration (no versus yes), AJCC
staging groups (Ia versus Ib versus IIa versus IIb versus
III), and initial level of hemoglobin in peripheral blood
(normal versus decreased) were tested as factors affecting
patient survival. For statistical reasons, myxoid and round
cell liposarcomas were analyzed together, because the
extent of myxoid/round cell component is generally con-
sidered a continuum of the same clinical/molecular entity;
the percentage of these cells is somewhat arbitrarily rec-
ognized, especially on the basis of Tru-cut biopsy [21],
because a major proportion of patients had recurrent tumor
or had undergone preoperative radiotherapy after biopsy.
All 181 patients were included in analysis without any
other preliminary selection. We first determined factors
influencing disease-specific survival (Table 2) and local
recurrence-free survival (Table 3) using univariate analy-
ses. The AJCC Stages IIb and III (p \ 0.001) (Fig. 1) and
Grade 3 tumors (p \ 0.001) were related to the shortest
disease-specific survival. In multivariate analysis of the
factors associated with survival after resection, we used
Cox proportional hazard models applying the stepwise
model-building procedure including all covariates signifi-
cant at the 10% level in univariate analysis. Two-way
interactions were then considered in the model. All statis-
tical analyses were performed using the R 2.11 statistical
program (R Development Core Team 2010; www.
R-project.org).
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Female 86.2% 78.0%–95.2% 0.05
Male 71.7% 60.8%–84.6%
Primary tumor site
Extremity 78.3% 70.7%–86.8% 0.96
Trunk wall 83.0% 66.5%–100.0%
Primary tumor site (extremities only)
Lower extremity 77.2% 69.2%–86.0% 0.19
Upper extremity 100.0% –
Histological grade




0–5 100.0% – 0.04
[ 5–50 75.8% 67.5%–85.2%
Tumor status at beginning of therapy in tertiary center
Primary tumor 79.4% 70.5%–89.3% 0.04




Biopsy before primary surgery
No 77.8% 67.3%–90.0% 0.62
Yes 81.0% 72.5%–90.5%
Radical surgery margins status
R0 80.5% 72.2%–88.6% 0.58
R1 77.5% 63.0%–95.3%
Histological subtype




No 80.6% 72.4%–87.6% 0.29
Yes 62.3% 35.5%–100.0%
AJCC staging groups





Initial level of hemoglobin
Decreased 76.6% 55.6%–100.0% 0.85
Normal 79.1% 71.5%–87.4%
R0 = microscopically radical resection; R1 = microscopically non-
radical, but macroscopically radical resection; AJCC = American
Joint Committee on Cancer.













Female 78.4% 68.4%–89.9% 0.29
Male 68.6% 56.0%–84.2%
Primary tumor site
Extremity 75.7% 67.1%–85.5% 0.10
Trunk wall 59.6% 39.7%–89.5%
Primary tumor site (extremities only)
Lower extremity 75.3% 66.2%–85.6% 0.59
Upper extremity 85.9% 69.5%–100.0%
Histological grade




0–5 84.6% 67.1%–100.0% 0.19
5–50 71.3% 61.8%–82.2%
Tumor status at beginning of therapy in tertiary center
Primary tumor 86.1% 78.5%–94.5% 0.01




Biopsy before primary surgery
No 58.1% 45.7%–74.0% \ 0.0001
Yes 86.1% 77.0%–96.3%
Radical surgery margins status
R0 77.5% 68.7%–87.4% 0.01
R1 60.9% 44.8%–82.6%
Histological subtype




No 76.2% 65.8%–83.8% 0.13
Yes 64.3% 40.9%–100.0%
AJCC staging groups





Initial level of hemoglobin
Decreased 76.1% 56.6%–99.7% 0.76
Normal 72.6% 63.5%–82.9%
R0 = microscopically radical resection; R1 = microscopically non-
radical, but macroscopically radical resection; AJCC = American
Joint Committee on Cancer.
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Results
Estimated 5-year disease-specific survival rate was 80%
(95% CI, 72.0%–86.7%), 5-year disease-free survival rate
was 58% (95% CI, 50.0%–67.2%), and 5-year local
relapse-free survival rate was 75% (95% CI, 66.0%–
83.1%). For local relapse-free survival we found five
important factors independently related to worse prognosis:
(1) clinically recurrent tumor (Fig. 2A); (2) high (Grade 2
or 3) histological grade; (3) surgical resection margins R1
(microscopically nonradical but macroscopically radical
resection) (Fig. 2B); (4) unplanned excision without pre-
operative biopsy (Fig. 2C); and (5) myxoid/round cell or
pleomorphic histologic subtype (Table 3). We identified
one independent factor that negatively influenced disease-
specific survival: AJCC Stage 3. For disease-free survival
we identified three independent negative prognostic fac-
tors: (1) histological Grade 3; (2) presence of clinical local
recurrence at the start of therapy in a sarcoma center; and
(3) tumor skin infiltration. For local relapse-free survival,
we found two independent factors with a negative impact:
(1) presence of clinical local recurrence at the start of
therapy in a sarcoma center; and (2) microscopically
positive margin after surgery (Table 4).
We found differences (p = 0.01) for local relapse-free
survival based on tumor status at the beginning of therapy
in the tertiary center: the 5-year local relapse-free survival
rate for a patient with a primary tumor treated in the sar-
coma center was 86.1%, for those after resection of the scar
after nonradical surgery at an outside sarcoma center it was
73.3%, and for clinical local relapse after primary surgery
at an outside sarcoma center it was 52.1%. For disease-
specific survival when calculated from the date of the first
surgery we found no difference (p = 0.14) among the three
groups: the 5-year disease-specific survival rate was 79.4
(95% CI, 70.5%–89.3%) for patients with a primary tumor
treatment in our center, 100% for those after wide scar
resection after unplanned nonradical surgery at an outside
hospital, and for clinical local relapse after primary surgery
at an outside sarcoma center 81.2% (95% CI, 70.7%–
93.3%).
Seventy-three of the 181 patients (40%) had recurrences
during followup, including 35 (19.3%) local recurrences.
We found differences in first recurrence pattern according
to liposarcoma pathological subtype; for the pleomorphic
type the most common were distant metastases (mainly to
lungs), myxoid/round cell type predominantly occurring in
local recurrences, and among distant metastases lung
metastases and abdominal wall/cavity metastases occurring
with a similar frequency (Table 5).
Discussion
Liposarcomas are a common histological type of soft tissue
sarcomas, occurring mainly in adults and presenting a wide
spectrum of clinical behavior. We have examined the
outcomes of localized, resectable liposarcomas of the
extremities or trunk wall treated with curative intent in a
tertiary referral sarcoma center and asked (1) which prog-
nostic factors influenced disease-specific survival, disease-
free survival, and local relapse-free survival, including new
AJCC staging system; (2) what was the impact of quality of
surgery and tumor status (primary versus clinically recur-
rent versus scar after inadequate surgery); and (3) what is
the type of disease recurrences according to pathological
subtype of liposarcoma?
We recognize limitations of our study. First, although
the study was retrospective, the patients were not
preselected and long-term followup in our series exceeded
the median time to recurrence, which in soft tissue sarco-
mas is usually not longer than 2 to 3 years. Overall and
local relapse-free survivals at 5 years were 80% and 75%,
respectively, which is similar or superior to other reported
series [8, 15, 22, 23]. Second, although there are concerns
about reliability of the AJCC staging system in sarcomas
[14], we have confirmed the prognostic value of this cur-
rent system. Third, tumor sites were limited to the
extremity and trunk wall, what might have an impact on
importance of some factors for patient prognosis, but it
consequently created a more homogenous group for anal-
ysis. Fourth, myxoid and round cell were not analyzed
separately, although round cell component has prognostic
Fig. 1 Kaplan-Meier curves show disease-specific survival according
to the AJCC staging system: 5-year DSS for Stage Ia and IIa was:
100%, for Ib: 93.4% (95% CI, 86.4%–100.0%), for IIb: 77.5% (95%
CI, 64.6%–93.0%), and for III: 58.5% (44.2%–77.3%). DSS =
disease-specific survival.
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value, but for statistical reasons, these two subtypes were
merged into one group, because the extent of myxoid/round
cell component is generally considered a continuum of the
same clinical/molecular entity; the percentage of these
Fig. 2A–C Kaplan-Meier curves show local recurrence-free survival
according to: (A) tumor status at treatment start in referral center (P =
primary tumor; W = clinical recurrence; W/B = scar after nonradical
prereferral resection); 5-year LRFS for primary tumor was: 86.1%
(95% CI, 78.5%–94.5%), for clinical recurrence: 52.1% (95% CI,
36.6%–74.3%), and for scar after nonradical surgery: 73.3% (95% CI,
53.6%–100.0%); (B) surgical margins (R0 = microscopically radical
resection; R1 = microscopically nonradical, but macroscopically
radical resection); 5-year LRFS for R0 was: 77.5% (95% CI, 68.7%–
87.4%), and for R1: 60.9% (95% CI, 44.8%–82.6%); (C) preoperative
biopsy (unplanned or planned surgery; N = no preoperative biopsy;
T = preoperative biopsy performed); 5-year LRFS for performed
preoperative biopsy was: 86.1% (95% CI, 77.0%–96.3%%) and for
lack of preoperative biopsy: 58.1% (95% CI, 45.7%–74.0%). LRFS =
local relapse-free survival.
b
Table 4. Multivariate analysis of prognostic factors for disease-




95% CI p value
DSS
Primary tumor
Clinical recurrence 1.124 0.540 2.340 0.760
Scar after nonradical
surgery
0.160 0.021 1.229 0.078
AJCC stage
2 2.117 0.706 6.345 0.180
3 5.772 2.075 16.057 0.001
DFS
Grade
2 versus 1 1.543 0.742 3.212 0.250
3 versus 1 3.808 1.925 7.531 0.000
Primary tumor
Clinical recurrence 2.219 1.317 3.737 0.003
Scar after nonradical
surgery
0.884 0.336 2.324 0.800
Skin infiltration
Yes versus no 2.795 1.380 5.661 0.004
LRFS
Primary tumor
Clinical recurrence 2.835 1.389 5.786 0.004
Scar after nonradical
surgery
1.436 0.458 4.503 0.530
R0/R1 margins
R1 versus R0 2.090 1.014 4.307 0.046
R0 = microscopically radical resection; R1 = microscopically non-
radical, but macroscopically radical resection; AJCC = American
Joint Committee on Cancer.
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cells is somewhat arbitrarily recognized, especially on the
basis of Tru-cut biopsy (which was used as preferential
method for preoperative diagnosis), and tumor grade was
included in multivariate analysis that interferes with
myxoid/round cell proportions.
Our data confirm the new AJCC staging system has
strong prognostic value in terms of disease-specific sur-
vival for liposarcomas of the extremities/trunk wall. It was
analyzed for the first time in literature regarding liposar-
comas (Table 6). Beyond well-established prognostic
factors such as tumor grade (the most reliable predictor of
disease-free survival) and size [3, 25], we have also iden-
tified additional prognostic factors regarding pathological
features, tumor status at presentation in the referral center,
and quality of surgery, which can be ultimately incorpo-
rated into future revisions of staging system. A noteworthy
finding is that sarcomatous skin infiltration (Fig. 3) is a
sign of aggressive behavior with a detrimental effect on
disease-free survival and it had also been indicated by
Ruka et al. [29] as an independent prognostic factor.
We confirmed an adverse impact of unplanned excision
not preceded by appropriate biopsy and imaging for
increasing the risk of local recurrences and that clinical
local recurrence is the most important prognostic factor for
subsequent local recurrence and disease-free survival [6, 8,
27, 28]. The tumor status (clinically recurrent versus pri-
mary) had also an impact on disease-specific survival in
univariate and with borderline significance in multivariate
analysis, which is similar to data from series of liposar-
comas from the National Cancer Institute, Milan, Italy [9].
The presence of clinically recurrent tumors is likely one of
the features of the aggressive behavior of liposarcoma and
definitely warrants multimodal therapy. The detrimental
effect of unplanned primary surgery is minimized by
reexcision of the scar with adjuvant radiotherapy, and these
patients do not have worse survival, which was also
observed in some reports [8, 33]. However, the impact of
the quality of surgery and status of the tumor at presenta-
tion in the sarcoma center on disease-specific survival is
less clear when calculated from the date of initial (first)
surgery; the obtained results were relatively good (5-year
disease-specific survival approximately 80%) independent
of the status at presentation in the sarcoma center [8]. We
must take into account two possible biases leading to this
result. First, patients referred after unplanned excision and
undergoing reexcision of the scar tend to have smaller,
anatomically favorably located or superficial tumors; this
likely explains better disease-specific survival and of
course this has an influence on lack of differences in dis-
ease-specific survival in the entire group of patients. The
group of patients after unplanned excision is also biased as
compared with primary tumors, because part of this group
before referral may develop metastatic disease and can
never be eligible for local therapy. Our data imply also the
importance of negative margins of resection with curative
intent. According to other series [15], it seems mostly
important in reoperations for recurrent lesions.
Liposarcoma pathological subtype is an important factor in
terms of prognosis and followup schedule; well-differentiated
liposarcomas located on the extremities/trunk wall have the
best prognosis, myxoid/round-cell liposarcomas intermediate,
and the poorest prognosis was observed for pleomorphic
liposarcomas. We have also confirmed that for myxoid/round
cell liposarcoma, local recurrences are the most common type
of relapse [22] and in case of recurrences, a high percentage of
relapse was observed in unusual extrapulmonary sites [9, 24,
30, 31]. This is contrary to pleomorphic liposarcoma, which
behaves as a typical high-grade sarcoma with a high propen-
sity to lung metastases. These subtypes differ also in
sensitivity to systemic chemotherapy (for instance, high
response rates approaching 50% on trabectedin are observed
in myxoid liposarcomas [11]) and radiotherapy [18, 26],
which may influence their outcomes after recurrences.
Myxoid/round-cell liposarcomas are the most common sub-
type of liposarcoma in the extremity/trunk wall localization,
which shows histologically continuous morphologic spec-
trum-sharing characteristic chromosome rearrangement
t(12;16) resulting in DDIT3-FUS (95%) or EWS-CHOP (5%)
fusion [1, 10, 13] with diagnostic and possible treatment
implications.
In conclusion, we have confirmed the value of the AJCC
staging system for predicting disease-specific survival in


















4 (14.8) 0 0 0 0 0
Myxoid/round cell
(104)
24 (23.1) 10 (9.6) 5 (4.8) 4 (3.8) 2 (2) 0
Pleomorphic (49) 7 (14.3) 13 (26.5) 1 (2) 1 (2) 1 (2) 2 (4)
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patients with liposarcomas of the extremity or trunk wall.
Wide reresection (plus radiotherapy) of the scar after
nonradical primary tumor resection results in acceptable
disease-free survival and local relapse-free survival in this
type of soft tissue sarcoma. Patients with unplanned exci-
sion have a higher risk of local and distant recurrences but
they can still be salvaged with a good final outcome when
referred to a sarcoma unit and treated in an aggressive,
combined way. We believe primary planned microscopi-
cally radical (R0) resection and multidisciplinary care in a
tertiary referral center is crucial in the management of
liposarcomas as well as all other soft tissue sarcomas.
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